Skip to main content
Cube Labs S.p.A. logo

Cube Labs S.p.A. — Investor Relations & Filings

Ticker · CUBE ISIN · IT0005532483 LEI · 815600566D45248BEB28 XMIL Professional, scientific and technical activities
Open in API
Filings indexed 136 across all filing types
Latest filing 2026-06-10 Proxy Solicitation & In…
Country IT Italy
Listing XMIL CUBE

About Cube Labs S.p.A.

https://cube-labs.com/

Cube Labs S.p.A. is a venture builder specializing in the healthcare technology and life sciences sectors. The company's model focuses on identifying promising academic research and development and transforming it into commercial enterprises. It creates and nurtures startups to bridge the gap between scientific discovery and market-ready healthcare solutions. The firm's investment and development activities cover key areas including pharmaceuticals, biotechnology, medical technology (MedTech), nutraceuticals, and the application of artificial intelligence in R&D. A core part of its mission is to make research, technologies, and tools more accessible, fostering open innovation and collaboration to accelerate the development of new healthcare technologies.

Recent filings

Filing Released Lang Actions
CUBE LABS S.P.A.:PUBBLICATO L’AVVISO DI CONVOCAZIONE DELL’ASSEMBLEA ORDINARIA DEGLI AZIONISTI 2026
Proxy Solicitation & Information Statement Classification · 92% confidence The document is a formal notice (‘avviso di convocazione’) of the 2026 Ordinary Shareholders’ Meeting, containing the agenda, procedures for participation, proxy instructions, and related disclosures to request votes. It is not the meeting results or actual reports but rather the solicitation and information statement for the upcoming AGM. This matches the Proxy Solicitation & Information Statement category (PSI).
2026-06-10 Italian
Internal Dealing - Filippo Surace
Director's Dealing Classification · 95% confidence The document is a regulatory disclosure detailing a personal share transaction by a person discharging managerial responsibilities (Filippo Surace) in accordance with EU Market Abuse Regulation requirements. It is a notification of insider dealing by a director, fitting the definition of "Director's Dealing" rather than a corporate report, earnings release, or company share buyback. Therefore, it should be classified as DIRS.
2026-06-10 Italian
CUBE LABS: BIODIAPERS OTTIENE LA CONCESSIONE DEL BREVETTO IN INDIA PER L’ARTICOLO ASSORBENTE INNOVATIVO CON FUNZIONE DI SEPARAZIONE E ISOLAMENTO DELLE FECI
Regulatory Filings Classification · 80% confidence The document is a press release (“Comunicato Stampa”) issued as regulated information on Euronext Growth Milan, announcing the grant of a patent in India by a subsidiary. It contains no financial results, proxy materials, management or board changes, capital operations, or detailed report content. It is not a report publication announcement but a general regulatory announcement/press release. Hence it falls under the fallback category Regulatory Filings (RNS).
2026-05-28 Italian
IL CONSIGLIO DI AMMINISTRAZIONE DI CUBE LABS APPROVA IL PROGETTO DI BILANCIO AL 31 DICEMBRE 2025
Annual Report Classification · 85% confidence The document is a regulated public disclosure by Cube Labs on Euronext Growth Milan, reporting and detailing the full‐year results for the fiscal year ended December 31, 2025. It contains comprehensive balance sheet, income statement, cash flow, net financial position data, portfolio breakdowns, and management commentary rather than merely highlighting key quarterly earnings. It is not a simple ‘earnings release’ or interim report, nor is it only an announcement pointing to an attached report. Instead, it constitutes the full annual financial report approved by the board of directors and publicly released. Therefore, it best fits the “Annual Report” category. FY 2025
2026-05-28 Italian
L’ASSEMBLEA STRAORDINARIA DEGLI AZIONISTI APPROVA UNA DELEGA AD AUMENTARE IL CAPITALE SOCIALE A PAGAMENTO PER UN IMPORTO COMPLESSIVO MASSIMO DI 15 MILIONI
Share Issue/Capital Change Classification · 92% confidence The document is a press release reporting the Extraordinary Shareholders’ Meeting resolution delegating the Board to increase the company’s share capital by up to €15 million (including possible exclusion of pre-emptive rights, new share classes, etc.). This is an announcement of a share issue / capital change. It is not a listing of financial results, an earnings release, nor a proxy or governance policy, but specifically concerns a capital increase. Therefore it falls under Share Issue/Capital Change (SHA).
2026-05-27 Italian
CUBE LABS S.P.A.: PUBBLICATO L’AVVISO DI CONVOCAZIONE DELL’ASSEMBLEA STRAORDINARIA DEGLI AZIONISTI 2026
Proxy Solicitation & Information Statement Classification · 85% confidence The document is a press release announcing and publishing the notice of convocation for an Extraordinary Shareholders’ Meeting, including agenda items, voting procedures, proxy instructions, record dates, and documentation availability. It is not the meeting minutes or results, nor a financial report. It serves as proxy solicitation/information materials requesting votes and providing details for shareholder participation. Therefore, it fits the definition of Proxy Solicitation & Information Statement (Code: PSI).
2026-05-12 Italian

Browse filings by year

4 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.